The TRIUMPH clinical program is Eli Lilly’s comprehensive Phase 3 trial umbrella for retatrutide (LY-3437943), an investigational triple-hormone receptor agonist targeting the GLP-1, GIP, and glucagon receptors. Unlike earlier GLP-1-only drugs such as semaglutide or dual agonists like tirzepatide, retatrutide engages three distinct metabolic pathways simultaneously to produce what researchers describe as a step-change in weight-loss pharmacology.<\/p>\n
The program currently comprises eight separate Phase 3 trials, designated TRIUMPH-1 through TRIUMPH-8, enrolling thousands of participants across multiple countries. These trials are designed to establish the safety and efficacy of retatrutide across a range of populations, from otherwise healthy adults with obesity to people with type 2 diabetes, osteoarthritis, established cardiovascular disease, and those needing long-term weight maintenance. The data generated by the TRIUMPH program will form the backbone of the U.S. Food and Drug Administration (FDA) New Drug Application (NDA) and comparable submissions to regulatory agencies worldwide.<\/p>\n
Retatrutide works by simultaneously activating three receptor types. GLP-1 receptor agonism improves insulin secretion and promotes satiety, GIP receptor agonism further enhances insulin sensitivity and energy disposal, and glucagon receptor agonism directly increases energy expenditure and promotes fat oxidation. This triple-hit mechanism has consistently produced weight loss outcomes that surpass those of any single or dual agonist tested to date (Coskun et al., Cell Metabolism, 2022; PMID: 35985340).<\/p>\n
Before the TRIUMPH program could begin, retatrutide first needed to prove its potential in Phase 2. The seminal Phase 2 trial, published in the New England Journal of Medicine in June 2023 (Jastreboff et al., NEJM, 2023; PMID: 37366315), enrolled 338 adults with obesity but without diabetes. Participants were randomized to receive once-weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks.<\/p>\n
The results were unprecedented. At the 12 mg dose, participants achieved a mean weight reduction of 24.2% from baseline. At 24 weeks, the 12 mg dose had already produced 17.5% mean weight reduction. Approximately 97% of participants on the 12 mg dose lost at least 5% of their body weight, 93% lost at least 10%, and 63% lost at least 20%. These figures placed retatrutide far ahead of any existing obesity pharmacotherapy at the time.<\/p>\n
The trial also established the graduated dose-escalation schedule that became the standard for all subsequent studies: starting at 2 mg for four weeks, then stepping up to 4 mg, then 8 mg, and finally 12 mg, with adjustments at four-week intervals over a 12-week titration period. This schedule was designed to minimize gastrointestinal side effects while allowing participants to reach therapeutic doses.<\/p>\n
A substudy published in The Lancet Diabetes & Endocrinology in 2025 (Coskun et al., Lancet Diabetes Endocrinol, 2025; PMID: 40609566) examined body composition changes in 281 participants with type 2 diabetes. At 36 weeks, retatrutide produced significant reductions in total body fat mass compared with placebo, with the 12 mg dose showing the most pronounced effects. Importantly, the fat loss was accompanied by preservation of lean body mass, a critical factor distinguishing retatrutide from simple caloric restriction, which typically results in disproportionate muscle loss.<\/p>\n
On May 21, 2026, Eli Lilly announced top-line results from TRIUMPH-1, the largest and most closely watched trial in the program. This was a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating retatrutide in adults with obesity or overweight with at least one weight-related comorbidity, excluding diabetes.<\/p>\n
The 12 mg dose of retatrutide produced a mean weight loss of 28.3% at 80 weeks. In a pre-specified subgroup of participants with a BMI of 35 or higher who remained on treatment, the mean weight loss reached 30.3% \u2014 approximately 85 pounds \u2014 at 104 weeks. This marked the first time any investigational obesity drug had crossed the 30% weight loss threshold in a Phase 3 setting.<\/p>\n
Secondary endpoints were equally compelling. Participants showed significant improvements in waist circumference, systolic blood pressure, and glycemic control markers including fasting glucose and HbA1c. The safety profile remained consistent with earlier Phase 2 data, with the most common adverse events being gastrointestinal (nausea, diarrhea, vomiting, constipation) and predominantly mild to moderate in severity. Discontinuation rates due to adverse events were comparable to or lower than those observed in earlier GLP-1 and dual-agonist trials, suggesting that the graduated titration schedule effectively manages tolerability (Lilly press release, May 21, 2026).<\/p>\n
Announced on December 11, 2025, TRIUMPH-4 was the first Phase 3 trial in the program to report results. It enrolled adults with obesity and knee osteoarthritis, a population of particular interest because of the well-established link between excess body weight and joint degeneration.<\/p>\n
The trial randomized participants to retatrutide 12 mg or placebo for 68 weeks. The primary endpoint was percent weight loss, with key secondary endpoints measuring changes in knee pain using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and physical function. Results showed a mean weight loss of 28.7% (71.2 pounds) in the treatment group, alongside statistically significant and clinically meaningful reductions in knee pain and improvements in physical function compared with placebo.<\/p>\n
The importance of TRIUMPH-4 extended beyond the weight-loss numbers. It demonstrated that retatrutide could meaningfully improve obesity-related comorbidities, strengthening the argument that the drug addresses not just body weight but also the downstream health consequences of obesity. This is critical for regulatory approval and for payer coverage decisions, because it positions retatrutide as a disease-modifying therapy rather than simply a weight-loss aid (Lilly press release, December 11, 2025).<\/p>\n
Two of the most anticipated ongoing trials in the program are TRIUMPH-2 and TRIUMPH-3, which extend retatrutide’s evaluation into populations with significant metabolic comorbidities.<\/p>\n
TRIUMPH-2<\/strong> is evaluating retatrutide in adults with obesity or overweight who also have type 2 diabetes. This is a critical population because people with diabetes historically lose less weight on incretin-based therapies than those without diabetes, likely due to differences in baseline metabolism and concurrent medications. The trial is expected to confirm the Phase 2 diabetes substudy findings and to demonstrate that the triple-receptor mechanism delivers meaningful weight loss and glycemic improvement even in this more treatment-resistant group. Results are anticipated in late 2026.<\/p>\n TRIUMPH-3<\/strong> is studying retatrutide in participants with obesity and established cardiovascular disease. This trial is particularly important for two reasons. First, demonstrating cardiovascular safety \u2014 or ideally, cardiovascular benefit \u2014 is increasingly expected for new obesity therapies by regulators. Second, the GLP-1 receptor class has already shown cardiovascular benefits in trials of semaglutide (SELECT) and tirzepatide (SURMOUNT-MMO), and retatrutide’s additional glucagon agonism may offer further advantages through enhanced energy expenditure and lipid metabolism. TRIUMPH-3 results are expected through 2026 and 2027 (ClinicalTrials.gov identifiers; Lilly trials portal).<\/p>\n TRIUMPH-5 addresses a question that is central to the long-term management of obesity: what happens after patients lose weight? The trial enrolls participants who have already achieved significant weight loss on retatrutide and then randomizes them to either continue the drug or switch to placebo, with both groups receiving lifestyle counseling.<\/p>\n The design reflects the reality that obesity is a chronic, relapsing disease. Previous trials of GLP-1 receptor agonists have shown that weight regain is substantial and rapid once treatment is discontinued \u2014 in some cases, patients regain two-thirds or more of lost weight within a year. TRIUMPH-5 is designed to determine whether continued retatrutide treatment can maintain the weight loss achieved during the initial treatment period, and if so, at what doses.<\/p>\n Unlike standard obesity trials that measure weight loss from baseline, TRIUMPH-5 measures weight regain from the randomization point. If retatrutide successfully maintains weight loss, it would provide strong evidence for the drug as a long-term therapy and would support labeling that includes weight maintenance as an approved indication.<\/p>\n Three additional trials round out the TRIUMPH program, each targeting specific populations and endpoints:<\/p>\n The safety profile observed across the TRIUMPH program has remained consistent with the Phase 2 data. The most commonly reported adverse events are gastrointestinal: nausea (occurring in approximately 30-40% of participants at the 12 mg dose), diarrhea (20-25%), vomiting (15-20%), and constipation (10-15%). These events are most common during the dose-escalation phase and tend to diminish over time as patients adjust.<\/p>\n Serious adverse events have been infrequent and generally not attributed to the study drug. No signals for pancreatitis, gallbladder disease requiring cholecystectomy, or medullary thyroid carcinoma have emerged in the Phase 3 data reported to date, though longer-term exposure data from the ongoing trials will be needed to fully characterize the risk profile. Mild increases in heart rate \u2014 a known class effect of GLP-1 receptor agonists \u2014 have been observed but without apparent clinical consequences in the trial populations studied.<\/p>\n A systematic review and meta-analysis of randomized controlled trials by Tewari et al. (Expert Review of Clinical Pharmacology, 2025; PMID: 39817343) concluded that retatrutide produces substantial weight loss with a manageable safety profile. Another meta-analysis by Abdrabou Abouelmagd et al. (Proceedings, 2025; PMID: 40291085) reported mean percentage weight loss between 15 and 24 percent across studies, with low rates of study discontinuation and infrequent serious adverse events.<\/p>\n Despite the impressive top-line results from TRIUMPH-1 and TRIUMPH-4, several critical pieces of the retatrutide puzzle remain incomplete:<\/p>\n The TRIUMPH program represents the most ambitious clinical development effort in obesity pharmacotherapy to date. With eight Phase 3 trials, thousands of participants, and a drug that engages three metabolic pathways simultaneously, it is attempting to answer questions that go beyond simple weight loss: can the drug improve comorbidities, maintain effect over years, and reduce cardiovascular events? If the early results are borne out by the complete dataset, retatrutide could fundamentally change how obesity is treated \u2014 from a condition managed primarily through lifestyle intervention and bariatric surgery to one in which highly effective pharmacotherapy is the standard of care.<\/p>\n For patients, the numbers are striking. A 30% weight loss \u2014 the figure now within reach for adherent patients on the 12 mg dose \u2014 is comparable to the results of bariatric surgery, without the surgical risks and recovery time. For healthcare systems, the potential reduction in obesity-related diseases \u2014 diabetes, hypertension, osteoarthritis, sleep apnea, cardiovascular disease \u2014 could represent one of the most significant public health interventions since the introduction of statins.<\/p>\n","protected":false},"excerpt":{"rendered":" What Is the TRIUMPH Clinical Program? The TRIUMPH clinical program is Eli Lilly’s comprehensive Phase 3 trial umbrella for retatrutide (LY-3437943), an investigational triple-hormone receptor agonist targeting the GLP-1, GIP, and glucagon receptors. Unlike earlier GLP-1-only drugs such as semaglutide or dual agonists like tirzepatide, retatrutide engages three distinct metabolic pathways simultaneously to produce what […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-19","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/19","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19"}],"version-history":[{"count":1,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/19\/revisions"}],"predecessor-version":[{"id":196,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/19\/revisions\/196"}],"wp:attachment":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}TRIUMPH-5: Weight Maintenance After Initial Loss<\/h2>\n
TRIUMPH-6, TRIUMPH-7, and TRIUMPH-8: The Pipeline Pipeline<\/h2>\n
\n
Safety Data Across the TRIUMPH Program<\/h2>\n
What Is Still Pending<\/h2>\n
\n
Summary: Why the TRIUMPH Program Matters<\/h2>\n